Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck.

Cancer treatment reviews·2026
Same author

<i>AXL</i>-mRNA Overexpression in Size-Based Enriched Circulating Tumor Cells as a Potential Biomarker for Anti-AXL Targeted Therapies in Non-Small-Cell Lung Cancer.

Cancers·2026
Same author

Different Pattern of Treatment Failure After Chemoradiation Between p16+ and p16- Patients Affected by Oropharyngeal Carcinoma.

Head & neck·2026
Same author

Correction: Anastasiou et al. MicroRNA Signatures and Machine Learning Models for Predicting Cardiotoxicity in HER2-Positive Breast Cancer Patients. <i>Pharmaceuticals</i> 2025, <i>18</i>, 1908.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

An observational retro-prospective study on patients with head and neck cancer who contracted COVID-19 (HERODOTUS: head and neck cancERs international cOviD-19 collabOraTion).

Oral oncology·2026
Same author

JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC.

Future oncology (London, England)·2026
Same journal

The Microbiome-Gut-Gonad Axis: How Microbial Metabolites Orchestrate Reproductive Physiology, Pathology, and Therapy.

The Journal of steroid biochemistry and molecular biology·2026
Same journal

L-arginine improves prenatal and pre-pubertal codeine-induced steroidogenesis deregulation by suppressing oxidative stress-dependent signaling in male wistar rats.

The Journal of steroid biochemistry and molecular biology·2026
Same journal

Discovery of 17-imidazo[1,2-a]pyridinyl-3α-hydroxy-5α-androstanes (17IPAs) as novel potent positive allosteric modulators of the GABA<sub>A</sub> receptor: Synthesis, in vitro and in silico studies.

The Journal of steroid biochemistry and molecular biology·2026
Same journal

Androgen receptor as therapeutic indicator for LAR-positive triple-negative breast cancer: Preclinical and clinical assessment.

The Journal of steroid biochemistry and molecular biology·2026
Same journal

The 24,25(OH)<sub>2</sub>D<sub>3</sub>-TLCD3B signaling complex and reproductive function in mice and men.

The Journal of steroid biochemistry and molecular biology·2026
Same journal

Testosterone and epitestosterone differentially regulate UDP-glucuronosyltransferases (UGT) activity.

The Journal of steroid biochemistry and molecular biology·2026
See all related articles

Related Experiment Video

Updated: Jul 5, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Molecular targets in lymphomas.

Amanda Psyrri1, Theofanis Economopoulos

  • 1Yale University School of Medicine, New Haven, CT, USA.

The Journal of Steroid Biochemistry and Molecular Biology
|May 13, 2008
PubMed
Summary
This summary is machine-generated.

Standard chemotherapy cures many lymphomas, but progress has stalled. Molecular biology advances offer new insights into lymphoma development, paving the way for novel molecular therapies to improve patient outcomes.

More Related Videos

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Related Experiment Videos

Last Updated: Jul 5, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • Lymphomas are a significant group of cancers with a substantial curable patient population using conventional chemotherapy.
  • Despite initial success, standard chemotherapy alone has reached a plateau in achieving higher cure rates for many lymphoma patients.

Purpose of the Study:

  • To explore the transformative potential of molecular therapy in treating lymphomas.
  • To highlight how recent advances in molecular biology are reshaping lymphoma treatment paradigms.

Main Methods:

  • Review of current literature on lymphoma pathogenesis and treatment.
  • Analysis of emerging molecular targets and therapies in preclinical and clinical studies.
  • Case examples illustrating the application of molecular therapy in lymphoma management.

Main Results:

  • Molecular biology has elucidated key pathways in lymphoma development.
  • Targeted therapies are emerging as promising alternatives or adjuncts to conventional chemotherapy.
  • Personalized treatment strategies based on molecular profiles are becoming feasible.

Conclusions:

  • Molecular therapy represents a paradigm shift in lymphoma treatment, moving beyond traditional chemotherapy.
  • A deeper understanding of lymphoma pathogenesis is crucial for developing more effective and targeted treatments.
  • The integration of molecular insights promises to overcome the limitations of current therapies and improve cure rates for lymphoma patients.